{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:53:44Z","timestamp":1791161624494,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,7,2]],"date-time":"2009-07-02T00:00:00Z","timestamp":1246492800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s00198-009-0991-1","type":"journal-article","created":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T11:51:50Z","timestamp":1246449110000},"page":"679-688","source":"Crossref","is-referenced-by-count":38,"title":["Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant\/persistent postmenopausal women in clinical practice versus randomized controlled trials"],"prefix":"10.1007","volume":"21","author":[{"given":"M. M.","family":"Wilkes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Navickis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M.","family":"Lewiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,7,2]]},"reference":[{"key":"991_CR1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"991_CR2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"991_CR3","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799\u20131809","journal-title":"N Engl J Med"},{"key":"991_CR4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1359\/jbmr.061008","volume":"22","author":"EV McCloskey","year":"2007","unstructured":"McCloskey EV, Beneton M, Charlesworth D et al (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 22:135\u2013141","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"991_CR5","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/8756-3282(93)90358-H","volume":"14","author":"C Cooper","year":"1993","unstructured":"Cooper C, O\u2019Neill T, Silman A (1993) The epidemiology of vertebral fractures. European Vertebral Osteoporosis Study Group. Bone 14(Suppl 1):S89\u2013S97","journal-title":"Bone"},{"key":"991_CR6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00198-006-0274-z","volume":"18","author":"SL Silverman","year":"2007","unstructured":"Silverman SL, Watts NB, Delmas PD et al (2007) Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 18:25\u201334","journal-title":"Osteoporos Int"},{"key":"991_CR7","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","volume":"15","author":"JJ Caro","year":"2004","unstructured":"Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003\u20131008","journal-title":"Osteoporos Int"},{"key":"991_CR8","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013\u20131022","journal-title":"Mayo Clin Proc"},{"key":"991_CR9","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1017\/S0266462300004694","volume":"9","author":"J Droitcour","year":"1993","unstructured":"Droitcour J, Silberman G, Chelimsky E (1993) A new form of meta-analysis for combining results from randomized clinical trials and medical-practice databases. Int J Technol Assess Health Care 9:440\u2013449","journal-title":"Int J Technol Assess Health Care"},{"key":"991_CR10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/sim.4780080502","volume":"8","author":"DD Ingram","year":"1989","unstructured":"Ingram DD, Kleinman JC (1989) Empirical comparisons of proportional hazards and logistic regression models. Stat Med 8:525\u2013538","journal-title":"Stat Med"},{"key":"991_CR11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","volume":"323","author":"NB Watts","year":"1990","unstructured":"Watts NB, Harris ST, Genant HK et al (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73\u201379","journal-title":"N Engl J Med"},{"key":"991_CR12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0002-9343(93)90350-X","volume":"95","author":"ST Harris","year":"1993","unstructured":"Harris ST, Watts NB, Jackson RD et al (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95:557\u2013567","journal-title":"Am J Med"},{"key":"991_CR13","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Broll J et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437\u20131443","journal-title":"N Engl J Med"},{"key":"991_CR14","first-page":"265","volume":"82","author":"HG Bone","year":"1997","unstructured":"Bone HG, Downs RW Jr, Tucci JR et al (1997) Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab 82:265\u2013274","journal-title":"J Clin Endocrinol Metab"},{"key":"991_CR15","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"991_CR16","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"991_CR17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","volume":"9","author":"HA Pols","year":"1999","unstructured":"Pols HA, Felsenberg D, Hanley DA et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461\u2013468","journal-title":"Osteoporos Int"},{"key":"991_CR18","doi-asserted-by":"crossref","first-page":"935","DOI":"10.7326\/0003-4819-131-12-199912210-00005","volume":"131","author":"P Ravn","year":"1999","unstructured":"Ravn P, Bidstrup M, Wasnich RD et al (1999) Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 131:935\u2013942","journal-title":"Ann Intern Med"},{"key":"991_CR19","first-page":"1895","volume":"85","author":"I Fogelman","year":"2000","unstructured":"Fogelman I, Ribot C, Smith R et al (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 85:1895\u20131900","journal-title":"J Clin Endocrinol Metab"},{"key":"991_CR20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J-Y Reginster","year":"2000","unstructured":"Reginster J-Y, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"991_CR21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"991_CR22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s001980170126","volume":"12","author":"J-Y Reginster","year":"2001","unstructured":"Reginster J-Y, Christiansen C, Roux C et al (2001) Intermittent cyclic tiludronate in the treatment of osteoporosis. Osteoporos Int 12:169\u2013177","journal-title":"Osteoporos Int"},{"key":"991_CR23","doi-asserted-by":"crossref","first-page":"742","DOI":"10.7326\/0003-4819-136-10-200205210-00009","volume":"136","author":"SL Greenspan","year":"2002","unstructured":"Greenspan SL, Schneider DL, McClung MR et al (2002) Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 136:742\u2013746","journal-title":"Ann Intern Med"},{"key":"991_CR24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653\u2013661","journal-title":"N Engl J Med"},{"key":"991_CR25","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"IC Chesnut","year":"2004","unstructured":"Chesnut IC, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"991_CR26","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1359\/jbmr.040116","volume":"19","author":"E McCloskey","year":"2004","unstructured":"McCloskey E, Selby P, Davies M et al (2004) Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 19:728\u2013736","journal-title":"J Bone Miner Res"},{"key":"991_CR27","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1185\/030079906X132370","volume":"22","author":"CH Boogaard van den","year":"2006","unstructured":"van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE et al (2006) Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 22:1757\u20131764","journal-title":"Curr Med Res Opin"},{"key":"991_CR28","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.bone.2007.07.009","volume":"41","author":"BA Briesacher","year":"2007","unstructured":"Briesacher BA, Andrade SE, Yood RA et al (2007) Consequences of poor compliance with bisphosphonates. Bone 41:882\u2013887","journal-title":"Bone"},{"key":"991_CR29","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1185\/030079906X167615","volume":"23","author":"DT Gold","year":"2007","unstructured":"Gold DT, Martin BC, Frytak JR et al (2007) A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 23:585\u2013594","journal-title":"Curr Med Res Opin"},{"key":"991_CR30","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00198-007-0421-1","volume":"18","author":"S Morin","year":"2007","unstructured":"Morin S, Rahme E, Behlouli H et al (2007) Effectiveness of antiresorptive agents in the prevention of recurrent hip fractures. Osteoporos Int 18:1625\u20131632","journal-title":"Osteoporos Int"},{"key":"991_CR31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00198-006-0230-y","volume":"18","author":"D Weycker","year":"2007","unstructured":"Weycker D, Macarios D, Edelsberg J et al (2007) Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 18:271\u2013277","journal-title":"Osteoporos Int"},{"key":"991_CR32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2125.2008.03178.x","volume":"66","author":"J Blouin","year":"2008","unstructured":"Blouin J, Dragomir A, Moride Y et al (2008) Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br J Clin Pharmacol 66:117\u2013127","journal-title":"Br J Clin Pharmacol"},{"key":"991_CR33","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1359\/jbmr.080418","volume":"23","author":"JR Curtis","year":"2008","unstructured":"Curtis JR, Westfall AO, Cheng H et al (2008) Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 23:1435\u20131441","journal-title":"J Bone Miner Res"},{"key":"991_CR34","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1359\/jbmr.080510","volume":"23","author":"AM Gallagher","year":"2008","unstructured":"Gallagher AM, Rietbrock S, Olson M et al (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23:1569\u20131575","journal-title":"J Bone Miner Res"},{"key":"991_CR35","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-007-0506-x","volume":"19","author":"V Rabenda","year":"2008","unstructured":"Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811\u2013818","journal-title":"Osteoporos Int"},{"key":"991_CR36","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s001980070097","volume":"11","author":"R Dowd","year":"2000","unstructured":"Dowd R, Recker RR, Heaney RP (2000) Study subjects and ordinary patients. Osteoporos Int 11:533\u2013536","journal-title":"Osteoporos Int"},{"key":"991_CR37","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/archinte.165.20.2414","volume":"165","author":"DH Solomon","year":"2005","unstructured":"Solomon DH, Avorn J, Katz JN et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165:2414\u20132419","journal-title":"Arch Intern Med"},{"key":"991_CR38","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s00198-004-1770-7","volume":"16","author":"RD Chapurlat","year":"2005","unstructured":"Chapurlat RD, Palermo L, Ramsay P et al (2005) Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int 16:842\u2013848","journal-title":"Osteoporos Int"},{"key":"991_CR39","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2006.11.001","volume":"40","author":"RR Recker","year":"2007","unstructured":"Recker RR, Kendler D, Recknor CP et al (2007) Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone 40:843\u2013851","journal-title":"Bone"},{"key":"991_CR40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","volume":"71","author":"JP Brown","year":"2002","unstructured":"Brown JP, Kendler DL, McClung MR et al (2002) The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103\u2013111","journal-title":"Calcif Tissue Int"},{"key":"991_CR41","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1185\/030079904125003566","volume":"20","author":"ST Harris","year":"2004","unstructured":"Harris ST, Watts NB, Li Z et al (2004) Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 20:757\u2013764","journal-title":"Curr Med Res Opin"},{"key":"991_CR42","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637\u2013645","journal-title":"JAMA"},{"key":"991_CR43","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.maturitas.2004.02.005","volume":"48","author":"JS McCombs","year":"2004","unstructured":"McCombs JS, Thiebaud P, McLaughlin-Miley C et al (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271\u2013287","journal-title":"Maturitas"},{"key":"991_CR44","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bone.2005.10.022","volume":"38","author":"KF Huybrechts","year":"2006","unstructured":"Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922\u2013928","journal-title":"Bone"},{"key":"991_CR45","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1001\/jama.293.18.2257","volume":"293","author":"HA Bischoff-Ferrari","year":"2005","unstructured":"Bischoff-Ferrari HA, Willett WC, Wong JB et al (2005) Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 293:2257\u20132264","journal-title":"JAMA"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-009-0991-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-009-0991-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-009-0991-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T19:01:05Z","timestamp":1558638065000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-009-0991-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,2]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["991"],"URL":"https:\/\/doi.org\/10.1007\/s00198-009-0991-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,2]]}}}